bioengineer.org /2 hours ago

Anti-PD-1 Therapy Modulates HIV-Specific CD8+ T Cells in Men with HIV

A clinical trial of anti-PD-1 therapy in men with HIV and cancer demonstrates complex changes in HIV-specific CD8+ T-cell phenotypes and clonal distribution.

Read source
fightaging.org /1 month ago

PD-L1 Blockade in the Brain Restores Measures of Glial Cell Function

PD-L1 found on the surface of cells is a well known immune checkpoint protein. When it binds to the receptor PD-1 found on the surface of T cells and B cells, it acts to suppress i...

Read source
bioengineer.org /1 week ago

Immunotherapy Combined With Chemotherapy Extends Survival in Advanced SMARCA4-Deficient Lung Cancer

A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in advanced SMARCA4-d...

Read source
sciencedaily.com /1 month ago

Bowel cancer “melted away” after immunotherapy, then stayed away

A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patient...

Read source
genengnews.com /3 days ago

Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice

Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse...

Read source
bioengineer.org /4 days ago

Local IL-12 and Flt3L mRNA Nanoparticles Control Checkpoint-Resistant Melanoma in Mice

Intratumoral co-administration of IL-12 and Flt3L mRNA lipid nanoparticles controlled anti-PD-1-refractory melanoma in mouse models by coordinating dendritic, natural killer, and T...

Read source
qchron.com /1 week ago

Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in a...

First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activa...

Read source
edtimes.in /1 month ago

First-Line Immunotherapy for Cancer: How the Treatment Order Is Changing in India

Mumbai (Maharashtra) [India], October 12: For much of the past two decades, immunotherapy was thought of as a treatment held in reserve — an option to try after chemotherapy and ra...

Read source
timesofindia.indiatimes.com /4 weeks ago

Biosimilar drugs breaking high-cost barrier to cancer immunotherapy

Recent changes in cancer care in India show an increase in immunotherapy prescriptions due to affordable biosimilars. Doctors report that the availability of cheaper versions of ni...

Read source
scmp.com /2 weeks ago

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in...

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
qchron.com /2 weeks ago

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibod...

Read source
qchron.com /1 month ago

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-...

Read source
genengnews.com /4 days ago

Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice

In mice, alcohol cut the efficacy of anti-PD-1 immunotherapy by roughly 50%, suppressing tumor-infiltrating and memory T cells while boosting TIGIT-carrying ones. Blocking TIGIT re...

Read source
peterattiamd.com /4 weeks ago

Personalized medicine comes to cancer immunotherapy

A phase III trial for personalized melanoma vaccination foreshadows a new era of cancer treatment The post Personalized medicine comes to cancer immunotherapy appeared first on Pe...

Read source
bioengineer.org /1 month ago

mRNA Vaccine Paired With Radiotherapy Shrinks HER2-Positive Lung Tumors in Mice

A HER2-targeted mRNA lipid nanoparticle vaccine combined with fractionated radiotherapy suppressed tumor growth and reprogrammed the immune microenvironment in a mouse model of HER...

Read source
bioengineer.org /1 month ago

IDO1 Inhibitor Plus Melanoma Vaccine Fails to Boost Tumor-Fighting T Cells in Trial

A carefully designed clinical trial that set out to supercharge the immune system’s attack on advanced melanoma has delivered a sobering but scientifically valuable verdict. Resear...

Read source
medcitynews.com /1 month ago

GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer

The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, wh...

Read source
bioengineer.org /1 month ago

Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails

An experimental oral cancer drug that disrupts a key molecular switch inside tumour cells, when paired with an established targeted therapy, has produced durable tumour shrinkage i...

Read source
healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
bioengineer.org /1 month ago

Immune Cells Cluster Around Blood Vessels to Predict Lung Cancer Immunotherapy Success

Immunotherapy has transformed the treatment landscape for non-small cell lung cancer, the most common form of lung malignancy worldwide, yet a stubborn problem persists: only a sub...

Read source
bioengineer.org /1 month ago

Staphylococcal Protein Reprograms Liver Tumor Macrophages to Boost Immunotherapy

One of the most stubborn obstacles in cancer immunotherapy is not the tumor cell itself but the cellular entourage that surrounds it. In hepatocellular carcinoma, the most common f...

Read source
biopharmadive.com /5 days ago

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval. 

Read source
newswire.com /1 week ago

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumorsP...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.